VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications.

VBL has pioneered and is actively developing three novel platform technologies.

The Company’s most advanced program is the anti-cancer gene-therapy program, in which VB-111 is the lead candidate. VB-111 is positioned to potentially treat a wide range of solid tumors.  VB-111 is conveniently administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients.  The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism may retain activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor.

VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VB-111 has also received an Orphan Designation for the treatment of ovarian cancer by the European Medicines Agency (EMA).

In December 2017,  VBL Therapeutics has launched OVAL, a potential-registration Phase 3 study of VB-111 in platinum resistant Ovarian Cancer in collaboration with the GOG Foundation, Inc.

In addition, VBL has developed two innovative programs that are based on our novel biological findings related to an exciting new highly specific protein called MOSPD2. Our finding unrevealed the role of MOSPD2 in controlling directed cell movement of immune and tumor cells. We are developing proprietary monoclonal antibodies targeting MOSPD2 for immune inflammatory diseases with proof-of-concept data in multiple sclerosis and preliminary data in other indications. In a second program, we are developing bi-specific antibodies that bring together tumor cells via MOSPD2 and T-cells via CD3, and thus recruits the immune system to fight tumor cells.

VBL has also developed a proprietary platform of investigational orally-available anti-inflammatory small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.

Founded in 2000, VBL is based in Modiin, Israel.